| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11010777 | Stem Cell Research | 2018 | 12 Pages |
Abstract
Resource TableUnique stem cell line identifierUHOMi001-AAlternative name(s) of stem cell lineiPCD02.30InstitutionInstitute for Regenerative Medicine & Biotherapy (IRMB), Montpellier, FRANCEContact information of distributorJohn De Vos john.devos@inserm.frType of cell lineiPSCOriginhumanAdditional origin infoAge: 34Sex: FemaleCell SourceDermal fibroblastsClonalityClonalMethod of reprogramminghOCT4, hSOX2, hC-MYC, hKLF4 (CytoTuneâ¢-iPS 2.0 Sendai Reprogramming Kit - Invitrogen, Thermo Fisher Scientific Inc.)Genetic ModificationYESType of ModificationSpontaneous mutationAssociated diseasePrimary Ciliary DyskinesiaGene/locusCompound Heterozygous mutations the Coiled-Coil Domain Containing 40 Gene (CCDC40): c.1116_1117delCT (Exon 7) and c.3180â¯+â¯1Gâ¯>â¯A (Intron 19)Method of modificationN/AName of transgene or resistanceN/AInducible/constitutive systemN/ADate archived/stock date2018-02-12Cell line repository/bankN/AEthical approvalThe study was approved by the regional scientific ethical committee (CPP Sud Med IV) under the number ID-RCB: 2013-A00892-43/CILIPS, Promoter University Hospital Of Montpellier) and informed consent was obtained from the patient.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Engi Ahmed, Caroline Sansac, Mathieu Fieldes, Anne Bergougnoux, Chloé Bourguignon, Joffrey Mianné, Cécile Arnould, Isabelle Vachier, Said Assou, Arnaud Bourdin, John De Vos,